Gene therapy is transforming the way we can treat many diseases, but immune responses to AAV vectors remain a critical challenge. Whether you're screening for pre-existing immunity, validating your vector, or preparing for regulatory submission, you need reliable, actionable data-and a partner who understands the stakes.
Today, we're proud to launch our comprehensive AAV Immunogenicity Assay Platform.
This new offering combines three powerful assays into a fully customized safety solution to help you move forward with clarity and confidence.